Pancreatic cancer is the 12th most common cancer in the world. The estimated five-year prevalence of people living with pancreatic cancer is 4.1 per 100,000, globally. This cancer is almost always fatal and is the seventh-most common cause of death from cancer. Pancreatic cancer is closely related to body fat and high BMI, thereby, being more prevalent in developed countries.

According to the World Journal of Oncology, in 2019, pancreatic cancer was the seventh-leading cause of death. According to the Globocan, in 2018, almost 458,918 cases of pancreatic cancers were recorded, worldwide. In Europe, the incidence rate of pancreatic cancer was observed to be 7.7 per 100,000 individuals. The extensive threat of pancreatic cancer is a major opportunity for companies to capitalize on the market, through the expansion of product portfolios and market penetration. The high patient pool and increasing trends of the same are expected to propel the market growth.

Key Market Trends

Targeted Therapy Segment is Expected to Exhibit the Fastest Growth Rate over the Forecast Period

  • Pancreatic cancer therapeutics is basically classified into chemotherapy, surgery, targeted therapy, and others.
  • The targeted therapy segment is expected to witness the fastest growth rate over the forecast period, owing to the higher efficacy, increasing rate of innovations, and speedy drug approvals.
  • Targeted therapy can be referred to as the treatment with the use of drugs or other biochemical substances, in order to identify and target specific cancerous cells, with no or minimal harm to the healthy cells surrounding the cancer cell.
  • For instance, tyrosine kinase inhibitors (TKIs) are a type of targeted therapy drugs that block the activity of cell growth in the cancerous cells. Erlotinib is an example of TKI used in targeted therapy, for the treatment of pancreatic cancer.



North America Dominated the Overall Market and is Expected to Retain its Dominance

  • North America dominated the pancreatic cancer therapeutics and diagnostics market. In North America, the United States dominates the market.
  • In the United States, the average lifetime risk of pancreatic cancer, for both men and women, is about 1 in 65 (1.5%). Pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of cancer deaths, according to the American Cancer Society.
  • The Pancreatic Cancer Action Network predicts pancreatic cancer to become the second-leading cause of cancer-related deaths in the United States, by 2020. With promising drugs in the pipeline, the US pancreatic cancer therapeutics and diagnostics market is expected to witness lucrative growth, during the forecast period.
  • The high healthcare spending and state-of-the-art healthcare facilities in the United States are expected to promote the growth of the market studied, indirectly. The country is also a hub for high-end R&D activities, which are anticipated to have a positive impact on novel product developments and clinical trials.



Competitive Landscape

The presence of major market players, such as Medtronic PLC, Apex Medical Corp., GE Healthcare (GE Company), Intersurgical Ltd, and ResMed, is intensifying the competition. The market players are adopting strategies, such as rising R&D investments, mergers, acquisitions, and product innovations, in order to sustain the increasing market rivalry.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support